Een crisis vraagt om samenwerking: hoe drie Oncode-onderzoekers helpen oplossingen voor COVID-19 te vinden
- Dutch translation of the English article - Al meer dan een half jaar is het vinden van oplossingen voor de huidige COVID-19-crisis een prioriteit, niet alleen in Nederland, maar in de hele wereld. Toen de laboratoria gesloten waren en het hele land in lockdown was, leverde dat een enorme druk op. Te midden van alle chaos besloten Oncode-onderzoekers Marvin Tanenbaum (samen met Wouter de Laat), Hans Clevers (werkzaam bij het Hubrecht Instituut) en Lude Franke (UMC Groningen) hun kennis en vaardigheden in te zetten.
A crisis calls for community: how three Oncode Investigators help find solutions for COVID-19
For more than half a year now, finding solutions to solve the current COVID-19 crisis is a priority - not only for the Netherlands, but for the entire world. With labs closed and the entire country in lockdown, the urgency and the pressure became almost tangible. In the midst of the chaos, Oncode Investigators Marvin Tanenbaum, Hans Clevers (both Hubrecht Institute) and Lude Franke (UMC Groningen) decided to put their knowledge and skills to good use.
Some subtypes of gastric/oesophageal adenocarcinoma responsive to immunotherapy
Interview with medical oncologist and Oncode Investigator Dr Sarah Derks. Gastric and oesophageal adenocarcinomas are a heterogeneous group, so it should come as no surprise that not all subtypes of gastric and oesophageal adenocarcinoma respond equally well to immunotherapy. Sarah explains why tumours that test positive for the Epstein-Barr virus and tumours with microsatellite instability are particularly responsive to immune checkpoint inhibitors.
Edwin Cuppen discusses tumour-agnostic drugs for cancer patients
Cancer medicine has traditionally focused on the site of a tumour, but in recent decades research has held out the promise of spotlighting its genetic background instead. The ultimate goal is to achieve more personalised treatment. Now that the first ‘tumour-agnostic drug’ has been authorised, that moment has finally arrived.
“We have underestimated the complexity of cancer.”
Anton Berns doesn’t sound like someone who is about to stop working. The 74 years old professor in Molecular Genetics talks with great enthusiasm about new technologies which, according to him, will drive the progress in cancer research the coming years.
Open Science: quicker access and more transparency
Oncode Investigator Bas van Steensel (NKI), is one of the Open Science advocates within Oncode Institute. Not a topic that is high on everyone's priority list, but that makes Bas extra passionate to explain the importance of it, and – not in the least – why researchers can benefit from it.
The Oncode Community Platform: Connecting researchers to create impact
Oncode Institute is a mission-driven research effort that goes beyond the competitive model of science. Within Oncode, researchers are strongly encouraged to work together because we need all available talent to outsmart cancer and impact patient’s lives. Oncode has co-created a digital tool with the research community that should help researchers find the expertise they need.
Scroll for more